EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Myeloid sarcoma shows a high frequency of mutations activating the MAPK / ERK pathway and association with clonal hematopoiesis

Dominik Nann iD, Tim-Colin Schade, Mathis Overkamp, Lejla Mahmutovic, Eyyub Bag, Stephan Forchhammer, Julia Slotta-Huspenina, Ludmila Boudova, Karl Sotlar, Leticia Quintanilla-Martinez iD, Irina Bonzheim iD, Falko Fend iD

The Journal of Pathology: Clinical Research · 2025

DOI: 10.1002/2056-4538.70044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology: Clinical Research, 2025. Verfasst von Dominik Nann und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology and Neuropathology, University Hospital Tuebingen and Comprehensive Cancer Center South West, Tuebingen, Germany. Hauptthemen laut MEDLINE: Sarcoma, Myeloid, MAP Kinase Signaling System, Clonal Hematopoiesis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Stemline Therapeutics GmbH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myeloid sarcoma (MS) is a mass‐forming extramedullary manifestation of myeloid blasts, either in relation to an underlying acute myeloid leukemia (AML), another myeloid neoplasm (MN) or as a de novo occurrence. Data on the genetic profile of MS are sparse. In this study, 41 MS of 34 patients, including 7 de novo cases and 24 patients with antecedent or synchronous MN, were analyzed with targeted next‐generation sequencing (NGS), RNA‐based fusion detection, and gene expression profiling (GEP). In 10 patients, a MS developed after stem cell transplantation for MN. Additionally, 21 available pre‐transplant bone marrow biopsies (BMB) from 20 patients and 6 post‐transplant BMB from 6 patients were investigated. The most frequently mutated gene was TET2 (41%), followed by NPM1 (38%) and NRAS (35%). Overall, 74% of the cases exhibited mutations affecting the MAPK/ERK pathway. AML‐type fusions were detected in seven MS patients, who were younger than those without fusions (median 49 versus 67 years). Nine of 13 patients with a MN and available pre‐transplant BMB showed additional mutations restricted to the MS, including an additional NRAS mutation in 3/5 cases with AML. Five of seven of patients with pre‐transplant BMB without evidence of a MN revealed clonal hematopoiesis (CH), mostly shared TET2 mutations. Comparative GEP between BM and MS revealed upregulation of the MAPK/ERK pathway in MS and of gene sets relevant for interaction with the microenvironment. In conclusion, MS is characterized by a high incidence of MAPK/ERK pathway mutations and activation, frequent clonal evolution, and association with CH in elderly patients without recurrent AML‐type fusions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sarcoma, MyeloidMAP Kinase Signaling SystemClonal HematopoiesisMutationGene Expression ProfilingHumansMaleFemaleInfantChild, PreschoolChildAdolescentYoung AdultAdultMiddle AgedAgedAged, 80 and overDNA Mutational AnalysisDNA-Binding ProteinsDioxygenasesNucleophosminMembrane ProteinsGTP Phosphohydrolases

Stichwörter der Autor:innen

bone marrow biopsyclonal evolutionclonal hematopoiesisgene expression profilingmutational analysismyeloid sarcoma

Substanzen

TET2 protein, humanDNA-Binding ProteinsDioxygenasesNPM1 protein, humanNucleophosminNRAS protein, humanMembrane ProteinsGTP Phosphohydrolases

Autor:innen und Institutionen

  • Institute of Pathology and Neuropathology, University Hospital Tuebingen and Comprehensive Cancer Center South West, Tuebingen, Germany.
  • Department of Dermatology, University Hospital Tübingen, Tübingen, Germany.
  • Institute of Pathology, Technical University of Munich, TUM School of Medicine, Klinikum rechts der Isar, Munich, Germany.
  • Institute of Pathology, Starnberg, Germany.
  • Biopticka Laboratory, Pilzen, Czech Republic.
  • Institute of Pathology, Paracelsus Medical University, Salzburg, Austria.

ORCID-Profile: Dominik Nann, Leticia Quintanilla-Martinez, Irina Bonzheim, Falko Fend

Förderung

  • Stemline Therapeutics GmbH

Zitieren

APA

Nann, D., Schade, T. C., Overkamp, M., Mahmutovic, L., Bag, E., Forchhammer, S., Slotta-Huspenina, J., Boudova, L., Sotlar, K., Quintanilla-Martinez, L., Bonzheim, I., & Fend, F. (2025). Myeloid sarcoma shows a high frequency of mutations activating the MAPK / ERK pathway and association with clonal hematopoiesis. The Journal of Pathology: Clinical Research. https://doi.org/10.1002/2056-4538.70044

Vancouver

Nann D, Schade TC, Overkamp M, Mahmutovic L, Bag E, Forchhammer S, et al. Myeloid sarcoma shows a high frequency of mutations activating the MAPK / ERK pathway and association with clonal hematopoiesis. The Journal of Pathology: Clinical Research. 2025. doi:10.1002/2056-4538.70044

BibTeX
@article{Nann2025,
  author = {Nann, Dominik and Schade, Tim-Colin and Overkamp, Mathis and Mahmutovic, Lejla and Bag, Eyyub and Forchhammer, Stephan and Slotta-Huspenina, Julia and Boudova, Ludmila and Sotlar, Karl and Quintanilla-Martinez, Leticia and Bonzheim, Irina and Fend, Falko},
  title = {Myeloid sarcoma shows a high frequency of mutations activating the MAPK / ERK pathway and association with clonal hematopoiesis},
  journal = {The Journal of Pathology: Clinical Research},
  year = {2025},
  doi = {10.1002/2056-4538.70044}
}
Kostenlos starten →